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Background. Renal dysfunction is an independent risk factor for mortality in patients hospitalized for heart failure. We sought to investigate the 
effects of hypertonic saline solution (NaCl 7,5%) for prevention of renal dysfunction in patients hospitalized with decompensated heart failure.
Methods. In a double-blind trial, 30 patients with decompensated heart failure (ejection fraction < 40%) were randomized (2:1) to receive a three-
day course of 100ml of hypertonic saline solution (HSS - NaCl 7,5%) twice daily or placebo (NaCl 0,9%), both followed by an intravenous bolus dose 
of furosemide, in addition to standard therapy. The primary end-point was an increase of serum creatinine over 0.3 mg/dL.
Results. 19 patients received HSS and 11 patients received placebo; 2 (10.5%) patients in HSS group and 5 (45.5%) in placebo group reached 
the primary end-point (absolute risk reduction 0.35, 95% CI 0.025-0.675). Creatinine levels remained stable during intervention in HSS group, and 
increased in placebo group (p=0.04; figure 1); urine output increased in HSS group (p=0.02); no difference between groups was found regarding 
serum sodium, BNP, osmolarity or BUN. Possible mechanims involved were explored with determination of serum C-cystatin, renin, vasopressin, 
angiotensin II, interleukin6 and TNF-alfa, and values did not differ between groups. 
Conclusions. The results of the present trial indicate a beneficial role of HSS for prevention of renal dysfunction in patients with decompensated 
heart failure.
